Three healthcare agencies have once again found themselves on the Inc. 5000 list in 2022 – CrowdPharm; Peregrine Market Access; and Rare Patient Voice. The Inc. 5000 ranks the nation’s fastest-growing private companies.
If you are not happy with the results below please do another search
50 search results for:
The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva’s COVID-19 vaccine.
Jazz Pharma is breaking new ground with its cannabidiol epilepsy treatment Epidiolex, taking the drug into a Phase III study in children and adolescents.
The United States will boost its supply of monkeypox vaccine by making an additional 1.8 million doses of Bavarian Nordic’s Jynneos vaccine available for ordering starting Aug. 22, the White House said on Thursday.
Researchers at Case Western University looked at the real-world experiences of 13,644 patients who were treated with Paxlovid or Lagevrio (molnupiravir) during the first half of 2022. The study was intended to determine the prevalence of three types of rebound outcomes with these two therapies, each of which has emergency use authorizations as treatments for COVID-19. In that study (currently in preprint on medRxiv, co-author Pamela Davis, M.D. and colleagues found that the 7-day and 30-day rebound rates associated with Paxlovid treatments, respectively, were 3.53% and 5.4% for COVID-19 reinfection; 2.31% and 5.87% for COVID-19 symptoms; and 0.44% and 0.77% for hospitalizations.
Genentech has signed an exclusive worldwide license agreement with Chinese pharmaceutical firm Jemincare to allow the latter to develop and commercialize JMKX002992, an androgen receptor degrader being developed for prostate cancer.
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns Jynneos, one of the two approved vaccines, may no longer be able to keep up, according to a report by Bloomberg.
The German constitutional court upheld the country’s measles vaccine mandate for children on Thursday, ruling against a challenge brought by parents.
The U.S. Department of Defense (DoD) has ended an encephalitis vaccine supply contract with Valneva, said the French drugmaker, adding that a slowdown in global travel activity, mainly affecting Asia, had led to lower demand.
The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a record $2.8 million.